Operating Lease, Liability, Current in USD of ELITE PHARMACEUTICALS INC /NV/ from Q1 2019 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.
Summary
ELITE PHARMACEUTICALS INC /NV/ quarterly Operating Lease, Liability, Current history and change rate from Q1 2019 to Q3 2025.
  • ELITE PHARMACEUTICALS INC /NV/ Operating Lease, Liability, Current for the quarter ending 30 Sep 2025 was $504K, a 19.2% increase year-over-year.
Operating Lease, Liability, Current, Quarterly (USD)
Operating Lease, Liability, Current, YoY Quarterly Change (%)

ELITE PHARMACEUTICALS INC /NV/ Quarterly Operating Lease, Liability, Current (USD)

Period Value YoY Chg Change % Date Report Filed
Q3 2025 $504K +$81.2K +19.2% 30 Sep 2025 10-Q 14 Nov 2025
Q2 2025 $488K +$71K +17% 30 Jun 2025 10-Q 14 Aug 2025
Q1 2025 $472K +$61K +14.8% 31 Mar 2025 10-Q 14 Nov 2025
Q4 2024 $457K +$431K +1644% 31 Dec 2024 10-Q 13 Feb 2025
Q3 2024 $422K +$420K +19425% 30 Sep 2024 10-Q 14 Nov 2024
Q2 2024 $417K +$408K +4754% 30 Jun 2024 10-Q 14 Aug 2024
Q1 2024 $411K +$397K +2659% 31 Mar 2024 10-K 30 Jun 2025
Q4 2023 $26.2K +$5.08K +24% 31 Dec 2023 10-Q 14 Feb 2024
Q3 2023 $2.16K -$22.9K -91.4% 30 Sep 2023 10-Q 14 Nov 2023
Q2 2023 $8.59K -$199K -95.9% 30 Jun 2023 10-Q 14 Aug 2023
Q1 2023 $14.9K -$188K -92.7% 31 Mar 2023 10-K 01 Jul 2024
Q4 2022 $21.1K -$133K -86.3% 31 Dec 2022 10-Q 14 Feb 2023
Q3 2022 $25.1K -$185K -88% 30 Sep 2022 10-Q 14 Nov 2022
Q2 2022 $207K +$1.55K +0.76% 30 Jun 2022 10-Q 15 Aug 2022
Q1 2022 $203K +$14.9K +7.9% 31 Mar 2022 10-K 29 Jun 2023
Q4 2021 $154K -$67.4K -30.5% 31 Dec 2021 10-Q 14 Feb 2022
Q3 2021 $210K -$7.08K -3.27% 30 Sep 2021 10-Q 15 Nov 2021
Q2 2021 $206K -$6.63K -3.12% 30 Jun 2021 10-Q 16 Aug 2021
Q1 2021 $188K -$20.1K -9.65% 31 Mar 2021 10-K 29 Jun 2022
Q4 2020 $221K +$17.2K +8.42% 31 Dec 2020 10-Q 16 Feb 2021
Q3 2020 $217K +$16.9K +8.46% 30 Sep 2020 10-Q 16 Nov 2020
Q2 2020 $212K +$16.6K +8.5% 30 Jun 2020 10-Q 14 Aug 2020
Q1 2020 $208K -$167K -44.5% 31 Mar 2020 10-K 14 Jun 2021
Q4 2019 $204K 31 Dec 2019 10-Q 10 Feb 2020
Q3 2019 $200K 30 Sep 2019 10-Q 12 Nov 2019
Q2 2019 $196K 30 Jun 2019 10-Q 09 Aug 2019
Q1 2019 $375K 02 Apr 2019 10-Q 09 Aug 2019
* An asterisk sign (*) next to the value indicates that the value is likely invalid.